From $172 to $20: Sarepta's Spectacular Fall
19/6 12:15
Sarepta Therapeutics (NASDAQ: SRPT) shares plunged 42% on Monday, June 16, following reports of a second patient death associated with its Duchenne muscular dystrophy gene therapy, Elevidys. In response, the biotechnology firm and its global partner Roche immediately suspended bo...